AIROS Medical

Executive Summary

AIROS Medical is a privately held US medical device company headquartered in San Diego, California, focused on pneumatic compression therapy for chronic vascular and lymphatic conditions. Founded in 2019, the company has developed FDA-cleared devices and garments for home use, treating lymphedema, venous disorders, and lipedema. In 2026, AIROS expanded its portfolio with the ARTAIRA line, targeting symptoms of Peripheral Arterial Disease (PAD), a major step into arterial disease management. The company's products aim to improve patient mobility and quality of life, offering convenient at-home therapy solutions. With a growing addressable market and an established regulatory pathway, AIROS is positioned to capture share in the compression therapy sector, which is driven by an aging population and increasing prevalence of chronic vascular conditions. As a private entity, the company has not disclosed funding or valuation, but its recent product expansion signals a strategic pivot into broader vascular care, potentially attracting partnership or investment interest. AIROS Medical's near-term focus is on commercializing the ARTAIRA line and penetrating the PAD treatment market, which represents a significant expansion beyond its core lymphatic and venous indications. The company's existing distribution network and brand recognition in home compression therapy provide a foundation for cross-selling. However, competition from larger medical device firms and reimbursement challenges remain. The conviction in AIROS’s growth trajectory is bolstered by its innovative product pipeline and the clear unmet need in PAD management. Key upcoming catalysts include initial sales traction for ARTAIRA, potential FDA clearances for additional indications, and strategic partnerships to accelerate market access. Overall, AIROS Medical is a compelling player in the respiratory and medical device space with a differentiated approach to vascular therapy.

Upcoming Catalysts (preview)

• Q3 2026ARTAIRA commercial launch and early sales traction for PAD indication85% success
• Q1 2027FDA clearance for expanded indications (e.g., pediatric lymphedema or post-surgical edema)60% success
• Q2 2026Strategic distribution partnership for European market entry70% success